CEVA Inc. (NASDAQ:CEVA), announced that CEVA management participated in 27th Annual ROTH Conference in Dana Point, California on Tuesday, March 10th. On Thursday shares of CEVA Inc. (NASDAQ:CEVA) closed at $22.77. Company’s sales growth for last 5 years was 5.70% and EPS growth for next 5 years is recorded as 29.70%.
Threshold Pharmaceuticals Inc. (NASDAQ:THLD) on Mar 03, reported a loss of $6 million in its fourth quarter. On a per-share basis, the South San Francisco, California-based company said it had a loss of 12 cents. Losses, adjusted for non-recurring gains, came to 14 cents per share. Threshold Pharmaceuticals Inc. (NASDAQ:THLD) in last trading activity advanced 0.22% to close at $4.54. Company weekly performance is -0.44% while its quarterly performance stands at 40.12%. Threshold Pharmaceuticals Inc. (NASDAQ:THLD) is -16.08% away from its 52 week high.
DigitalGlobe (NYSE:DGI), announced that its management presented at the Piper Jaffray Technology, Media & Telecommunications Conference in New York on Tuesday, March 10, 2015 at 11:00 a.m. ET. On last trading day DigitalGlobe, Inc. (NYSE:DGI) decreased -1.87% to close at $34.11. Its volatility for the week is 2.23% while volatility for the month is 3.41%. DGI’s sales growth for past 5 years was 18.40% and its EPS growth for past 5 years was -29.90%. DigitalGlobe, Inc. (NYSE:DGI) monthly performance is 16.94%.
Quest Diagnostics Inc. (NYSE:DGX), has launched its first whole exome sequencing assay service – Neurome – a test that facilitates the diagnosis of rare neurological disorders which primarily affects pediatric patients. Quest Diagnostics Inc. (NYSE:DGX) has 0.40% insider ownership. In last trading activity company’s stock closed at $72.59.
Pharmaceutical giant Pfizer, Inc. (NYSE:PFE) revealed in a regulatory filing on Thursday that Chairman and Chief Executive Officer Ian Read received a 2014 total compensation that grew 23 percent from last year, reflecting strong increase in pension accrual, and a slight increase in salary. On Thursday shares of Pfizer Inc. (NYSE:PFE) closed at $34.00. Company’s sales growth for last 5 years was 0.10% and EPS growth for next 5 years is recorded as 2.17%.